收费全文 | 32696篇 |
免费 | 1811篇 |
国内免费 | 810篇 |
耳鼻咽喉 | 342篇 |
儿科学 | 668篇 |
妇产科学 | 1149篇 |
基础医学 | 7969篇 |
口腔科学 | 723篇 |
临床医学 | 2261篇 |
内科学 | 3223篇 |
皮肤病学 | 520篇 |
神经病学 | 1809篇 |
特种医学 | 610篇 |
外科学 | 1785篇 |
综合类 | 3592篇 |
一般理论 | 3篇 |
预防医学 | 4527篇 |
眼科学 | 322篇 |
药学 | 3387篇 |
9篇 | |
中国医学 | 560篇 |
肿瘤学 | 1858篇 |
2023年 | 338篇 |
2022年 | 656篇 |
2021年 | 859篇 |
2020年 | 894篇 |
2019年 | 804篇 |
2018年 | 823篇 |
2017年 | 928篇 |
2016年 | 857篇 |
2015年 | 1006篇 |
2014年 | 1878篇 |
2013年 | 1929篇 |
2012年 | 1710篇 |
2011年 | 2060篇 |
2010年 | 1627篇 |
2009年 | 1648篇 |
2008年 | 1730篇 |
2007年 | 1573篇 |
2006年 | 1407篇 |
2005年 | 1193篇 |
2004年 | 1057篇 |
2003年 | 962篇 |
2002年 | 700篇 |
2001年 | 679篇 |
2000年 | 643篇 |
1999年 | 575篇 |
1998年 | 566篇 |
1997年 | 537篇 |
1996年 | 556篇 |
1995年 | 566篇 |
1994年 | 534篇 |
1993年 | 449篇 |
1992年 | 424篇 |
1991年 | 359篇 |
1990年 | 323篇 |
1989年 | 286篇 |
1988年 | 257篇 |
1987年 | 211篇 |
1986年 | 171篇 |
1985年 | 250篇 |
1984年 | 240篇 |
1983年 | 145篇 |
1982年 | 140篇 |
1981年 | 131篇 |
1980年 | 117篇 |
1979年 | 106篇 |
1978年 | 78篇 |
1977年 | 65篇 |
1976年 | 55篇 |
1974年 | 38篇 |
1973年 | 35篇 |
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献Methods: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge.
Results: Overall, mortality (16.2% vs. 5.3%; p?<?.01), median hospital LOS (42.0 vs. 26.0 days; p?<?.01) and median total costs ($173,144 vs. $98,982; p?<?.01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups.
Conclusion: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT. 相似文献